

# THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

11<sup>th</sup> ImmunoTherapy of Cancer Conference  
April 3 - 5, 2025 • Munich, Germany



CCC MÜNCHEN  
COMPREHENSIVE  
CANCER CENTER



WOLFGANG  
WILMANN'S  
STIFTUNG



Deutsches Konsortium für  
Translationale Krebsforschung



CECOG ACADEMY  
Central European Cooperative Oncology Group

## SCIENTIFIC PROGRAMME



## JOIN US AT ITOC11!

The 11th ImmunoTherapy of Cancer Conference (ITOC11) to be held from April 3 - 5, 2025 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC11 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TzM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON, the Wolfgang Wilmanns Stiftung as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.



*See you there!*



# ITOC11 COMMITTEES

## ITOC11 Conference President

- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

## ITOC11 Chairmen of the Scientific Committee


- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (TZM, Munich, Germany)

## ITOC11 Scientific Committee

- Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
- Michael Bergmann (Medical University Vienna, Austria)
- Mascha Binder (Universitätsspital Basel, Switzerland)
- Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
- Alexander Eggermont (Cancer Center Amsterdam, The Netherlands)
- Ulrich Jäger (Medical University of Vienna, Austria)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Johanna Olweus (Institute for Cancer Research, University of Oslo, Norway)
- Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
- Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
- José Saro (CMO LCB-Novimmune, Switzerland)
- Stefani Spranger (Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA, United States)
- Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
- Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

## ITOC Association Board Members

- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)
- Christoph Zielinski (Medical University of Vienna, Austria)



- 08.30 Registration Opens**
- 09.30 - 09.40 Welcome Address:** Michael von Bergwelt, Munich, Germany
- 09.40 - 11.10 Plenary Session 1: Tumor Immunology Inside: Novel Players**
- 09.40 – 10.10 01.01. Neutrophils in cancer  
Béatrice Zitti, Geneva, Switzerland
- 10.10 – 10.40 01.02. Dendritic cells as orchestrators of cancer immunity  
Niroshana Anandasabapathy, New York, NY, United States
- 10.40 – 11.10 01.03. Tregs in the cancer environment  
Eliane Piaggio, Paris, France
- 11.10 - 11.40 Coffee Break
- 11.40 - 13.10 Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies**
- 11.40 - 12.10 02.01. The influence of circadian rhythm on IO agent efficacy  
Christoph Scheiermann, Geneva, Switzerland
- 12.10 - 12.40 02.02. Androgen influence on immunotherapy  
Megan Ruhland, Portland, OR, United States
- 12.40 - 13.10 02.03. Local production of glucocorticoids in cancer and its therapeutic relevance  
Matthew Taves, Bethesda, MD, United States
- 13.10 - 13.40 Satellite Symposium - Slot 1**
- 13.40 - 15.00 Lunch & Poster Viewing
- 15.00 - 17.00 Plenary Session 3: New Targets and New Leads**
- 15.00 - 15.30 03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy  
Zihai Li, Columbus, OH, United States
- 15.30 - 16.00 03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging  
Matteo Iannacone, Milan, Italy
- 16.00 – 16.15 03.03. UCHL1 hijacks tolerogenic dendritic cell maturation and promotes mregDC-Treg crosstalk to nullify checkpoint Blockade  
Yufei Zhao, Shanghai, China
- 16.15 – 16.30 03.04. KLK4 cleaves CXCR3 chemokines and confers immune escape and resistance to cancer immunotherapy  
Tobias Dreyer, Munich, Germany
- 16.30 – 16.45 03.05. Exploring immunotherapy resistance in primary and metastatic oral cancer using organoid technology  
Lili Szabó, Würzburg, Germany
- 16.45 – 17.00 03.06. Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy  
Melissa Maxwell, Marlborough, United States
- 17.00 - 18.00 Plenary Session 4: Polyspecific Antibody Derivatives**
- 17.00-17.30 04.01. TCR and TCR mimetics x CD3 bispecific antibodies: Expand the reach of antibodies to intracellular targets  
José Saro Suarez, Geneva, Switzerland
- 17.30-18.00 04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer  
Hans van der Vliet, Amsterdam, The Netherlands
- 18.00 - 20.00 Networking Event and Poster Viewing (at the venue)**



## 08.00 – 08.30 Satellite Symposium - Slot 2

### 08.30 – 09.30 Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy

08.30 – 09.00 05.01. Pro-local immunotherapies  
Louisa von Baumgarten, Munich, Germany

09.00 – 09.30 05.02. Pro systemic immunotherapy  
Mascha Binder, Basel, Switzerland

### 09.30 – 10.30 Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy

09.30 – 10.00 06.01. Triggering alpha2adrenergic receptors for tumor rejection  
Jingjing Zhu, Louvain, Belgium

10.00 – 10.30 06.02. Neuro-immune regulation of ILC function in anti-tumor immunity  
Camilla Jandus, Geneva, Switzerland

10.30 – 11.00 Coffee Break

### 11.10 – 12.30 Plenary Session 7: Immune Monitoring – Omics Technology

11.00 – 11.30 07.01. Spatial profiling of the immune contexture in cancer: a novel translational way to attack 'cold' tumors  
Niels Halama, Heidelberg, Germany

11.30 – 12.00 07.02. Resolving the HLA-ligandome in cancer  
Juliane Walz, Tübingen, Germany

12.00 – 12.30 07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer  
Pedro Romero, Lausanne, Switzerland

## 12.30 - 13.00 Satellite Symposium - Slot 3 | Option 1 (30min)

## 12.30 - 13.30 Satellite Symposium - Slot 3 | Option 2 (60min)

13.00/13.30 – 14.30 Lunch & Poster Viewing

### 14.30 – 15.15 Plenary Session 8: ITOC 11 Lifetime Achievement Award

Advancing Cancer Therapy: From Cancer Immunoediting to Personalized Cancer Vaccines  
Robert D. Schreiber, St. Louis, MO, United States


### 15.15 - 16.30 Plenary Session 9: Advancing Cancer Vaccines

15.15 – 15.45 09.01. Neoantigen selection in tumor and lessons from flu  
Paul G. Thomas, Memphis, TN, United States

15.45 – 16.15 09.02. Dysfunctional translation generates aberrant, immunogenic peptides  
Tanja de Gruijl, Amsterdam, The Netherlands

16.15 – 16.30 09.03. Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma  
Laura de Freitas Chama, Tübingen, Germany

16.30 - 17.00 Coffee Break





FRIDAY, APRIL 4, 2025

**17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)**

- 17.00 – 17.15 10.01. CD44v6-specific CAR-NK cells: a novel approach to precision medicine in bladder cancer  
Iris Lodewijk, Madrid, Spain
- 17.15 – 17.30 10.02. Targeting CSF1R+ myelo-monocytic cells enhances CAR-T cell response in B cell lymphoma  
David Stahl, Cologne, Germany
- 17.30 – 17.45 10.03. Immunosensitizing effect of TLR agonist combination for the treatment of cold tumors  
Thomas Morin, Dijon, France
- 17.45 – 18.00 10.04. Adapter P329G-directed CAR T cells for modular targeting of lung cancer  
Sophia Stock, Munich, Germany

**18.00 - 19.00 Poster Viewing with Presenters**

**19.15 ITOC 11 Conference Dinner**



## 08.00 – 09.00 Plenary Session 11: What Cellular Therapies Need to Work

08.00 – 08.30 11.01. The role of preconditioning in T cell therapy  
Michal Besser, Tel Aviv, Israel

08.30 – 09.00 11.02. The role of myeloid cells in CAR T cell failure  
Camille Bigenwald, Villejuif, France

## 09.00 – 10.30 Plenary Session 12 Engineering novel Cellular Immunotherapies

09.00 – 09.30 12.01. Novel targets of TCR therapies  
Johanna Olweus, Oslo, Norway

09.30 – 10.00 12.02. Adoptive Cell Therapy, ways to enhance them  
Sabine Heitzeneder, Stanford, CA, United States

10.00 – 10.30 12.03. RORing cancer with novel CAR T cells  
Michael Hudecek, Würzburg, Germany

10.30 – 11.00 Coffee Break

## 11.00 – 12.30 Plenary Session 13: Advancing Cellular Therapies with Combinations

11.00 – 11.30 13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors  
Andreas Mackensen, Erlangen, Germany

11.30 – 12.00 13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies  
Robert Zeiser, Freiburg, Germany


12.00 – 12.15 13.03. Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells  
Silvia Menegatti, Suresnes, France

12.15 – 12.30 13.04. Silencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self-delivering RNAi approach  
Melissa Maxwell, Marlborough, United States

12.30 – 12.45 13.05. Autocrine glucocorticoid signaling in hormonally active cancers induces antigen expression for CAR-T cell therapy  
Marc Schauer, Würzburg, Germany

## 12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks

## 13.15 – 14.15 Lunch & Farewell



# SAVE THE DATES!

Mark your calendars and save the dates for the

## 11<sup>th</sup> ImmunoTherapy of Cancer Conference in 2025!

Join us as we convene once again to advance research, foster collaboration, and drive innovation in the field of cancer immunotherapy. Get ready to connect with leading experts, explore cutting-edge discoveries, and shape the future of cancer treatment.

Stay tuned for more details on the 2025 conference that promises to inspire, educate, and propel us closer to our shared goal of conquering cancer through immunotherapy.

#ITOC2025 #Immunotherapy #SaveTheDate

